Equivocal, explicit and emergent actions of PKC isoforms in cancer

Peter J. Parker*, Sophie J. Brown, Veronique Calleja, Probir Chakravarty, Mathias Cobbaut, Mark Linch, Jacqueline J.T. Marshall, Silvia Martini, Neil Q. McDonald, Tanya Soliman, Lisa Watson

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

36 Citations (Scopus)


The maturing mutational landscape of cancer genomes, the development and application of clinical interventions and evolving insights into tumour-associated functions reveal unexpected features of the protein kinase C (PKC) family of serine/threonine protein kinases. These advances include recent work showing gain or loss-of-function mutations relating to driver or bystander roles, how conformational constraints and plasticity impact this class of proteins and how emergent cancer-associated properties may offer opportunities for intervention. The profound impact of the tumour microenvironment, reflected in the efficacy of immune checkpoint interventions, further prompts to incorporate PKC family actions and interventions in this ecosystem, informed by insights into the control of stromal and immune cell functions. Drugging PKC isoforms has offered much promise, but when and how is not obvious.

Original languageEnglish
Pages (from-to)51-63
Number of pages13
Issue number1
Publication statusPublished - Jan 2021


Dive into the research topics of 'Equivocal, explicit and emergent actions of PKC isoforms in cancer'. Together they form a unique fingerprint.

Cite this